cultivate(MD) is excited announce a significant milestone achieved by one of our portfolio companies, SentiAR. The Valley Hospital in Ridgewood, New Jersey, has become the first in the state and one of the pioneers in the United States to treat a patient using SentiAR’s FDA-cleared holographic cardiac ablation visualization platform, CommandEP.
This groundbreaking procedure marks the first instance of pulsed field atrial fibrillation ablation performed in the world using the CommandEP platform.
The procedure was performed by Dr. Dan Musat, Associate Director of Electrophysiology at The Valley Hospital and Director of Electrophysiology Research for Valley Health System.
The CommandEP system, developed by SentiAR, represents the world’s first FDA-cleared, holographic, augmented reality (AR) platform designed to enhance the efficiency of cardiac ablation procedures. This cutting-edge technology allows electrophysiologists to wear AR glasses, providing an interactive, hands-free holographic view of the patient’s heart. The system integrates seamlessly with existing electroanatomic mapping systems (EAMS) to create a real-time, three-dimensional model of the heart, guiding physicians with unprecedented precision.
Dr. Musat emphasized the importance of adopting advanced technologies to improve patient care, stating, “Our team of electrophysiologists at Valley perform more than 750 cardiac ablations a year to treat arrhythmias. We are regularly adopting the latest technology to advance the high-level care we provide our patients. This commitment to advancing our patient’s safety and outcomes led to our adoption of the SentiAR system. The system provides our electrophysiology team with an interactive visual of the patient’s heart, helping to guide where we will ablate the heart during our procedure.”
Berk Tas, CEO of SentiAR highlighted the transformative impact of the CommandEP system on cardiac electrophysiology. “SentiAR is adding the capability for physicians to view all information during their procedures through the SentiAR interface. This in turn enhances control and efficiency of cardiac electrophysiology ablation procedures.”
cultivate(MD) is proud to be a lead investor in SentiAR, supporting its mission to advance medical technology and improve patient care. This landmark achievement underscores the commitment of both SentiAR and cultivate(MD) to driving innovation in the medical device sector.